Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vivatides Therapeutics

Request full access

Extrahepatic RNA therapeutics beyond the liver

Woburn, United StatesFounded 2025Biotech & Life Sciences

About Vivatides Therapeutics

Vivatides Therapeutics is a biotechnology company founded in 2025, with operations in Suzhou, China and the Boston area (Woburn, Massachusetts), that develops RNA therapeutics designed to reach tissues beyond the liver. Traditional RNA medicines have largely been limited to liver-targeted applications because of delivery challenges; Vivatides has built a proprietary extrahepatic delivery platform spanning both siRNA and antisense oligonucleotides (ASO), with advances in ligand conjugation, delivery efficiency, tissue-targeting specificity and safety, and encouraging in vivo results. Combined with sequence-design and target-discovery capabilities, the platform supports a diversified pipeline aimed at large chronic indications such as hyperlipidemia and hypertension, as well as oncology. The company was founded by Dr Keming Zhou, and its leadership team includes experts from leading RNA therapeutics companies who have led or played key roles in multiple extrahepatic RNA programmes. Vivatides raised a seed round of about $10 million led by Apricot Capital in 2025, then on 10 April 2026 announced an oversubscribed $54 million Series A co-led by Qiming Venture Partners and a leading industry fund, with Highlight Capital, TF Capital and existing investor Apricot Capital. Proceeds fund preclinical optimisation and IND-enabling studies, pipeline progression toward the clinic and expansion of its global R&D and management teams. Sources: PR Newswire 10 Apr 2026; PharmCube (2025 seed).

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Drug Development, Genetics and genomics, RNA, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEEDOther financing Aug 2025 $10M $40M Apricot Capital · Qiming Venture Partners ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Vivatides Therapeutics team growth

Vivatides Therapeutics's team grew 50% over the past year.

1-year team growth+50%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vivatides Therapeutics in the Woburn ecosystem

Live from Dealroom

The Vivatides Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

Employees 3 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vivatides Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vivatides Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.